Covalon Technologies (CVE:COV) Is In A Good Position To Deliver On Growth Plans
May 01
Canadian (TSX) Biotech Industry Analysis
UpdatedMay 02, 2024
DataAggregated Company Financials
Companies28
- 7D3.4%
- 3M5.4%
- 1Y-39.6%
- YTDn/a
Over the last 7 days, the Biotech industry has risen 6.8%, driven by gains from Medicenna Therapeutics of 52%. Meanwhile, Defence Therapeutics actually underperformed within the industry, shrinking 14% in the last week. In contrast, the industry has lost 36% in the last 12 months. Earnings are forecast to grow by 38% annually.
Industry Valuation and Performance
Has the Canadian Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 02 May 2024 | CA$916.5m | CA$78.8m | -CA$302,067,618.09 | 12.6x | -3x | 11.6x |
| Sat, 30 Mar 2024 | CA$1.1b | CA$88.5m | -CA$315,945,403.12 | 11.1x | -3.6x | 12.7x |
| Mon, 26 Feb 2024 | CA$1.2b | CA$93.1m | -CA$320,866,772.99 | 12.6x | -3.7x | 12.6x |
| Wed, 24 Jan 2024 | CA$3.6b | CA$86.3m | -CA$516,788,684.00 | 6.6x | -6.9x | 41.4x |
| Fri, 22 Dec 2023 | CA$3.6b | CA$86.2m | -CA$522,022,024.00 | 6.9x | -6.9x | 41.6x |
| Sun, 19 Nov 2023 | CA$3.8b | CA$86.7m | -CA$545,065,480.00 | 5.5x | -7x | 44x |
| Tue, 17 Oct 2023 | CA$3.8b | CA$88.9m | -CA$531,777,608.00 | 5.7x | -7.2x | 43.2x |
| Thu, 14 Sep 2023 | CA$3.9b | CA$87.3m | -CA$506,277,536.00 | 5.8x | -7.8x | 45.2x |
| Sat, 12 Aug 2023 | CA$4.0b | CA$85.8m | -CA$521,748,945.00 | 6.9x | -7.6x | 46.3x |
| Mon, 10 Jul 2023 | CA$4.1b | CA$81.6m | -CA$517,313,568.00 | 13.1x | -7.9x | 50.1x |
| Wed, 07 Jun 2023 | CA$3.9b | CA$86.5m | -CA$553,541,221.00 | 12.6x | -7.1x | 45.3x |
| Fri, 05 May 2023 | CA$3.8b | CA$82.5m | -CA$585,085,399.00 | 11.2x | -6.5x | 46x |
| Sun, 02 Apr 2023 | CA$2.4b | CA$90.6m | -CA$601,991,593.00 | 9.8x | -4.1x | 27x |
| Tue, 28 Feb 2023 | CA$2.7b | CA$90.4m | -CA$590,103,690.00 | 8.5x | -4.5x | 29.7x |
| Thu, 26 Jan 2023 | CA$3.2b | CA$87.5m | -CA$525,162,814.00 | 11.6x | -6.1x | 36.4x |
| Sat, 24 Dec 2022 | CA$3.1b | CA$87.6m | -CA$534,356,825.00 | 10.3x | -5.7x | 34.8x |
| Mon, 21 Nov 2022 | CA$3.1b | CA$88.1m | -CA$573,631,677.00 | 13.5x | -5.4x | 35.2x |
| Wed, 19 Oct 2022 | CA$3.1b | CA$86.2m | -CA$553,040,785.00 | 14.8x | -5.7x | 36.5x |
| Fri, 16 Sep 2022 | CA$3.5b | CA$85.0m | -CA$538,378,999.00 | 13.5x | -6.5x | 41.1x |
| Sun, 14 Aug 2022 | CA$3.5b | CA$84.2m | -CA$509,953,638.00 | 10x | -6.9x | 41.9x |
| Tue, 12 Jul 2022 | CA$3.3b | CA$182.1m | -CA$607,530,489.00 | 11x | -5.5x | 18.2x |
| Thu, 09 Jun 2022 | CA$3.2b | CA$177.6m | -CA$589,157,406.00 | 13.7x | -5.4x | 18x |
| Sat, 07 May 2022 | CA$3.3b | CA$181.8m | -CA$476,363,622.00 | 13.5x | -6.9x | 18.1x |
| Mon, 04 Apr 2022 | CA$3.5b | CA$170.2m | -CA$480,725,757.00 | 15.3x | -7.2x | 20.3x |
| Wed, 02 Mar 2022 | CA$3.3b | CA$167.1m | -CA$468,864,072.00 | 16.1x | -7x | 19.6x |
| Fri, 28 Jan 2022 | CA$3.2b | CA$167.7m | -CA$433,590,070.00 | 18.7x | -7.3x | 19x |
| Sun, 26 Dec 2021 | CA$3.8b | CA$168.6m | -CA$433,300,964.00 | 22.9x | -8.8x | 22.7x |
| Tue, 23 Nov 2021 | CA$6.0b | CA$170.5m | -CA$468,540,649.00 | 5.5x | -12.9x | 35.4x |
| Thu, 21 Oct 2021 | CA$7.9b | CA$244.1m | -CA$608,109,446.00 | 7.4x | -13.1x | 32.5x |
| Sat, 18 Sep 2021 | CA$8.2b | CA$242.7m | -CA$610,153,831.00 | 6.7x | -13.4x | 33.6x |
| Mon, 16 Aug 2021 | CA$3.5b | CA$161.7m | -CA$473,092,915.08 | 27.5x | -7.3x | 21.4x |
| Mon, 31 May 2021 | CA$4.1b | CA$147.0m | -CA$495,024,670.75 | 10.8x | -8.3x | 28.1x |
Price to Earnings Ratio
-8.9x
Current Industry PE
- Investors are pessimistic on the Canadian Biotechnology industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 31.9x is higher than the industry's current PS ratio of 11.8x.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have improved over the last three years.
- Meanwhile revenues for these companies have declined 20% per year.
- This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.
Industry Comparison
How does Canadian Biotech compare with similar industries?
| CA Market | -0.54% | |
| Healthcare | 6.19% | |
| Biotech | 3.37% | |
| Biotech | 3.37% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| MDNA Medicenna Therapeutics | CA$2.31 | 20.3% +CA$27.2m | 131.0% | PB8.6x | |
| GLAB Gemina Laboratories | CA$0.60 | 20.0% +CA$7.4m | -3.2% | PE-6.9x | |
| COV Covalon Technologies | CA$1.23 | 26.8% +CA$6.4m | -38.8% | PS1.2x | |
| HBP Helix BioPharma | CA$0.22 | 12.8% +CA$5.7m | 10.0% | PB81.2x | |
| EDT Spectral Medical | CA$0.45 | 4.7% +CA$5.6m | 67.9% | PS77.8x |